PI is executing a stepped rollout of its flagship diagnostic test for diabetic kidney disease. Successful commercialisation of PromarkerD provides the opportunity to enjoy ongoing returns through licensing fees and royalty payments, which will grow as the test is adopted by more physicians and licen...See more